Business Description
ENDRA Life Sciences Inc
NAICS : 334510
SIC : 8071
ISIN : US29273B5003
Share Class Description:
NDRA: Registered ShsTotal Employee Number:
11Description
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.26 | |||||
Debt-to-EBITDA | -0.07 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 89.7 | |||||
3-Year EPS without NRI Growth Rate | 90.3 | |||||
3-Year FCF Growth Rate | 88.3 | |||||
3-Year Book Growth Rate | -91.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.5 | |||||
9-Day RSI | 51.77 | |||||
14-Day RSI | 51.87 | |||||
3-1 Month Momentum % | 6.2 | |||||
6-1 Month Momentum % | 19.33 | |||||
12-1 Month Momentum % | -23.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.64 | |||||
Quick Ratio | 0.64 | |||||
Cash Ratio | 0.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -737.8 | |||||
Shareholder Yield % | -81.71 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -490.46 | |||||
ROA % | -239.65 | |||||
ROIC % | -347.14 | |||||
3-Year ROIIC % | -424.03 | |||||
ROC (Joel Greenblatt) % | -1191.16 | |||||
ROCE % | -276.27 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.63 | |||||
EV-to-EBIT | -1.04 | |||||
EV-to-EBITDA | -1.07 | |||||
EV-to-Forward-Revenue | 20.41 | |||||
EV-to-FCF | -1.35 | |||||
Earnings Yield (Greenblatt) % | -96.15 | |||||
FCF Yield % | -75.42 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NDRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ENDRA Life Sciences Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.15 | ||
| Beta | -0.0902 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -0.91 | ||
| Volatility % | 74.63 | ||
| 14-Day RSI | 51.87 | ||
| 14-Day ATR ($) | 0.589253 | ||
| 20-Day SMA ($) | 5.15625 | ||
| 12-1 Month Momentum % | -23.15 | ||
| 52-Week Range ($) | 2.96 - 9.85 | ||
| Shares Outstanding (Mil) | 1.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ENDRA Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ENDRA Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-12-09 10:00 | In 139 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 112 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 21 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 5.74 (+0.61%) | ||
| Fourth quarter earnings results for 2025 | 2026-04-01 | 4.65 (-2.52%) | ||
| Annual report for 2025 | 2026-03-31 | 4.68 (+7.59%) | ||
| General meeting for 2024 | 2025-12-09 10:00 | 5.48 (-10.16%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 6.57 (+5.29%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 4.38 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-16 | 3.21 (+2.56%) |
Show
Entries
ENDRA Life Sciences Inc Frequently Asked Questions
What is ENDRA Life Sciences Inc(NDRA)'s stock price today?
The current price of NDRA is $5.32. The 52 week high of NDRA is $9.85 and 52 week low is $2.96.
When is next earnings date of ENDRA Life Sciences Inc(NDRA)?
The next earnings date of ENDRA Life Sciences Inc(NDRA) is 2026-08-14 Est..
Does ENDRA Life Sciences Inc(NDRA) pay dividends? If so, how much?
ENDRA Life Sciences Inc(NDRA) does not pay dividend.
Guru Commentaries on NAS:NDRA
No articles.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers